Immutep Completes Single Ascending Dose Portion of Phase One Autoimmune Disease Therapy Candidate Study; Shares Rise 5%

MT Newswires Live

03/19

Immutep (ASX:IMM) completed the single ascending dose portion of its first-in-human phase one study evaluating its IMP761 therapy candidate, with dosing up to 14 milligrams per kilogram, according to a Thursday Australian bourse filing.

The therapy candidate was well tolerated across all dose levels, and no safety concerns or dose-limiting toxicities were observed. The study is currently progressing in the multiple ascending dose portion, which is expected to be completed in the September quarter. This portion is evaluating the pharmacokinetics and safety of IMP761 across two dose levels.

IMP761 is a LAG-3 agonist antibody that enhances the physiological inhibitory function of LAG-3 on T-cell receptor signaling, potentially suppressing pathogenic T-cell responses in autoimmune diseases.

Its shares jumped 5% in recent trading on Thursday.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2620292812"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620292812\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620292812?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-19 09:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620292812","market":"sh","top_or_hot":-1,"title":"Immutep Completes Single Ascending Dose Portion of Phase One Autoimmune Disease Therapy Candidate Study; Shares Rise 5%","media":"MT Newswires Live","content":"<html><body><p> Immutep (ASX:IMM) completed the single ascending dose portion of its first-in-human phase one study evaluating its IMP761 therapy candidate, with dosing up to 14 milligrams per kilogram, according to a Thursday Australian bourse filing.</p><p>The therapy candidate was well tolerated across all dose levels, and no safety concerns or dose-limiting toxicities were observed. The study is currently progressing in the multiple ascending dose portion, which is expected to be completed in the September quarter. This portion is evaluating the pharmacokinetics and safety of IMP761 across two dose levels.</p><p>IMP761 is a LAG-3 agonist antibody that enhances the physiological inhibitory function of LAG-3 on T-cell receptor signaling, potentially suppressing pathogenic T-cell responses in autoimmune diseases.</p><p>Its shares jumped 5% in recent trading on Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immutep Completes Single Ascending Dose Portion of Phase One Autoimmune Disease Therapy Candidate Study; Shares Rise 5%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmutep Completes Single Ascending Dose Portion of Phase One Autoimmune Disease Therapy Candidate Study; Shares Rise 5%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-03-19 09:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Immutep (ASX:IMM) completed the single ascending dose portion of its first-in-human phase one study evaluating its IMP761 therapy candidate, with dosing up to 14 milligrams per kilogram, according to a Thursday Australian bourse filing.</p><p>The therapy candidate was well tolerated across all dose levels, and no safety concerns or dose-limiting toxicities were observed. The study is currently progressing in the multiple ascending dose portion, which is expected to be completed in the September quarter. This portion is evaluating the pharmacokinetics and safety of IMP761 across two dose levels.</p><p>IMP761 is a LAG-3 agonist antibody that enhances the physiological inhibitory function of LAG-3 on T-cell receptor signaling, potentially suppressing pathogenic T-cell responses in autoimmune diseases.</p><p>Its shares jumped 5% in recent trading on Thursday.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMM.AU","symbol_name":"IMMUTEP LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2620292812","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620292812","pubTimestamp":1773883807,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Immutep  completed the single ascending dose portion of its first-in-human phase one study evaluating its IMP761 therapy candidate, with dosing up to 14 milligrams per kilogram, according to a Thursday Australian bourse filing.The therapy candidate was well tolerated across all dose levels, and no safety concerns or dose-limiting toxicities were observed. The study is currently progressing in the multiple ascending dose portion, which is expected to be completed in the September quarter. This portion is evaluating the pharmacokinetics and safety of IMP761 across two dose levels.IMP761 is a LAG-3 agonist antibody that enhances the physiological inhibitory function of LAG-3 on T-cell receptor signaling, potentially suppressing pathogenic T-cell responses in autoimmune diseases.Its shares jumped 5% in recent trading on Thursday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IMM.AU":"IMMUTEP LTD","BK7067":"生物科技","BK7508":"医药生物股"},"translate_title":"Immutep完成一期自身免疫性疾病候选疗法研究的单次递增剂量部分；股价上涨5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMM.AU":1},"content_text":"Immutep (ASX:IMM) completed the single ascending dose portion of its first-in-human phase one study evaluating its IMP761 therapy candidate, with dosing up to 14 milligrams per kilogram, according to a Thursday Australian bourse filing.The therapy candidate was well tolerated across all dose levels, and no safety concerns or dose-limiting toxicities were observed. The study is currently progressing in the multiple ascending dose portion, which is expected to be completed in the September quarter. This portion is evaluating the pharmacokinetics and safety of IMP761 across two dose levels.IMP761 is a LAG-3 agonist antibody that enhances the physiological inhibitory function of LAG-3 on T-cell receptor signaling, potentially suppressing pathogenic T-cell responses in autoimmune diseases.Its shares jumped 5% in recent trading on Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}